Disperazol will be collaborating with Biophys Ltd to develop its second generation antibiofilm asset to manipulate cyclic-di-nucleotide levels in Gram-negative bacterial cells in order to prevent biofilm formation or to dismantle mature biofilms.

Biophys, with its expanding Class 2 microbiology laboratory based at the Cardiff MediCentre in Cardiff, Wales, offers Disperazol Pharma a development opportunity to rapidly test its next generation assets to move from hit-to-lead to lead optimisation.

Biophys will start testing Disperazol Pharma’s new library of compounds using novel reporter strains of Pseudomonas aeruginosa and Escherichia coli from early 2026.

We are excited to have joined the AMR Industry Alliance. The team at Disperazol has more than 40 years of experience across fundamental research and translational development of antibacterial compounds. We are pleased to be able to join our global partner organisations in the AMR Industry Alliance to co-create new ways of working that will help to overcome the scientific challenges of creating new antimicrobials and taking these to market.

…

We are proud to have been selected by CC4CARB (https://www.cc4carb-collection.org/) to support the development of our next generation compounds to reduce cyclic-di-GMP levels in Gram-negative bacteria.